Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
Pharmacogenomics and Personalized Medicine · 2021-05 · Volume 14 · 569-577
DOI: 10.2147/pgpm.s224894 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacogenomics and Personalized Medicine, 2021-05. Verfasst von David F Kisor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Manchester University, Department of Pharmaceutical Sciences and Pharmacogenomics, Fort Wayne, IN, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Manchester University, Department of Pharmaceutical Sciences and Pharmacogenomics, Fort Wayne, IN, USA.
- North Dakota State University, College of Health Professions, Department of Pharmacy Practice, Fargo, ND, USA.
- Sanford Imagenetics, Sioux Falls, ND, USA.
- Ferris State University, Department of Pharmaceutical Sciences, Big Rapids, MI, USA.
ORCID-Profile: Natasha J Petry, David R Bright
Zitieren
APA
Kisor, D. F., Petry, N. J., & Bright, D. R. (2021). Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example. Pharmacogenomics and Personalized Medicine, Volume 14, 569-577. https://doi.org/10.2147/pgpm.s224894
Vancouver
Kisor DF, Petry NJ, Bright DR. Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example. Pharmacogenomics and Personalized Medicine. 2021;Volume 14:569-577. doi:10.2147/pgpm.s224894
BibTeX
@article{Kisor2021,
author = {Kisor, David F and Petry, Natasha J and Bright, David R},
title = {Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example},
journal = {Pharmacogenomics and Personalized Medicine},
year = {2021},
volume = {Volume 14},
pages = {569--577},
doi = {10.2147/pgpm.s224894}
}
EUVIMED